𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Imatinib Mesylate in Combination with Other Chemotherapeutic Agents for Chronic Myelogenous Leukemia

✍ Scribed by Tetsuzo Tauchi; Kazuma Ohyashiki

Book ID
111835330
Publisher
Carden Jennings Publishing
Year
2004
Tongue
English
Weight
89 KB
Volume
79
Category
Article
ISSN
0925-5710

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Persistent neutropenia in chronic myelog
Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
✍ Yu-Yan Hwang; Eric Tse; Jason C.C. So; Thomas S.K. Wan; Yok-Lam Kwong πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 110 KB πŸ‘ 1 views

A physician or a group of physicians considers presentation and evolution of a real clinical case, reacting to clinical information and data (boldface type). This is followed by a discussion/commentary.

Imatinib mesylate therapy reduces bone m
Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia
✍ Carlos E. Bueso-Ramos; Jorge Cortes; Moshe Talpaz; Susan O'Brien; Francis Giles; πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 189 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Reticulin‐stained bone marrow fibrosis is associated with a poor prognosis in patients with chronic myelogenous leukemia (CML). Resolution of fibrosis with therapy may improve patient outcome. ## METHODS The effect of imatinib therapy on bone marrow fibrosis was evaluat